Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It clinical development pipeline includes XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy comprising treatment-resistant adult and pediatric focal seizures, rare and pediatric forms of epilepsy, and other neurological disorders; and XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of epilepsy. The company also develops GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN007, a central nervous system (CNS)-acting calcium channel blocker that directly modulates Cav2.1, which is a critical calcium channel implicated in the pathophysiology of hemiplegic migraine, a rare and debilitating neurological disorder. Xenon Pharmaceuticals Inc. has collaboration agreements with Genentech, Inc. and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300
Debt
Debt-to-Equity Ratio0.41
Current Ratio20.83
Quick Ratio20.83
Price-To-Earnings
Trailing P/E Ratio-7.59
Forward P/E Ratio-10.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$310,000.00
Price / Sales838.74
Cash FlowN/A
Price / CashN/A
Book Value$2.00 per share
Price / Book6.75
Profitability
EPS (Most Recent Fiscal Year)($1.72)
Net Income$-30,700,000.00
Net Margins-9,872.67%
Return on Equity-95.43%
Return on Assets-55.94%
Miscellaneous
Employees81
Outstanding Shares19,260,000
Market Cap$270.62 million
Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How were Xenon Pharmaceuticals' earnings last quarter?
Xenon Pharmaceuticals Inc (NASDAQ:XENE) issued its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.04. Xenon Pharmaceuticals had a negative return on equity of 95.43% and a negative net margin of 9,872.67%. View Xenon Pharmaceuticals' Earnings History.
When is Xenon Pharmaceuticals' next earnings date?
What price target have analysts set for XENE?
2 analysts have issued 12-month price targets for Xenon Pharmaceuticals' stock. Their predictions range from $15.00 to $16.00. On average, they anticipate Xenon Pharmaceuticals' stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 14.8% from the stock's current price. View Analyst Price Targets for Xenon Pharmaceuticals.
What is the consensus analysts' recommendation for Xenon Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenon Pharmaceuticals.
Who are some of Xenon Pharmaceuticals' key competitors?
Some companies that are related to Xenon Pharmaceuticals include Zai Lab (ZLAB), Vanda Pharmaceuticals (VNDA), Apellis Pharmaceuticals (APLS), Rhythm Pharmaceuticals (RYTM), Aptinyx (APTX), Eagle Pharmaceuticals (EGRX), Geron (GERN), MacroGenics (MGNX), Rocket Pharmaceuticals (RCKT), Revance Therapeutics (RVNC), TG Therapeutics (TGTX), Assembly Biosciences (ASMB), Amphastar Pharmaceuticals (AMPH), CannTrust (CNTTF) and Cara Therapeutics (CARA).
Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the folowing people:
- Dr. Simon N. Pimstone, CEO & Director (Age 50)
- Mr. Ian C. Mortimer, Pres, CFO, COO & Company Sec. (Age 42)
- Mr. Robin P. Sherrington, Exec. VP of Bus. & Corp. Devel. (Age 57)
- Dr. James R. Empfield, Sr. VP of Drug Discovery of Xenon Pharmaceuticals USA Inc (Age 57)
- Ms. Jodi Regts B.A., MBA, VP of Corp. Affairs & Investor Relations
Has Xenon Pharmaceuticals been receiving favorable news coverage?
Media coverage about XENE stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Xenon Pharmaceuticals earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Xenon Pharmaceuticals.
Who are Xenon Pharmaceuticals' major shareholders?
Xenon Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.45%), Acuta Capital Partners LLC (3.18%), DAFNA Capital Management LLC (2.08%), State of New Jersey Common Pension Fund D (1.09%), Point72 Asset Management L.P. (0.55%) and NJ State Employees Deferred Compensation Plan (0.35%). Company insiders that own Xenon Pharmaceuticals stock include Bvf Partners L P/Il, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Institutional Ownership Trends for Xenon Pharmaceuticals.
Which institutional investors are selling Xenon Pharmaceuticals stock?
Which institutional investors are buying Xenon Pharmaceuticals stock?
XENE stock was acquired by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Renaissance Technologies LLC, State of New Jersey Common Pension Fund D, JBF Capital Inc., NJ State Employees Deferred Compensation Plan, Elmwood Wealth Management Inc., Spark Investment Management LLC and Kovack Advisors Inc.. Company insiders that have bought Xenon Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Insider Buying and Selling for Xenon Pharmaceuticals.
How do I buy shares of Xenon Pharmaceuticals?
Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xenon Pharmaceuticals' stock price today?
One share of XENE stock can currently be purchased for approximately $13.50.
How big of a company is Xenon Pharmaceuticals?
Xenon Pharmaceuticals has a market capitalization of $270.62 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-30,700,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Xenon Pharmaceuticals employs 81 workers across the globe.
How can I contact Xenon Pharmaceuticals?
Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]
MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
